The Detection of Minimal Residual Disease with Flow Cytometry and the Relationship Between Prognosis and Minimal Residual Disease in Bone Marrow in Advanced Neuroblastoma

CAI Jiao-yang,TANG Yan-jing,JIANG Li-min,SONG De-lian,PAN Ci,CHEN Jing,DONG Lu,ZHOU Min,XUE Hui-liang,GU Long-jun,TANG Jing-yan

DOI: https://doi.org/10.3969/j.issn.1673-5501.2006.03.005

2006-01-01

Abstract:Objective To establish a method to investigate whether flow cytometry detection of minimal residual disease(MRD) in bone marrow(BM) could predict prognosis and clinically guide the risk-adjusted therapy for neuroblastoma(NB) patients. Methods Human TGW NB cell line was used to detect the immunophenotype of NB cells by flow cytometry (FCM). The FCM sensitivity of the cocktail of CD45~ FITC /CD81~ PE /CD56~ PECy5+ was tested in our lab. The results of MRD with FCM were used to evaluate neuroblastoma metastasis in BM at diagnosis and during chemotherapy.Results The TGW cell line expressed CD56 and CD81 antigen and did not express CD45. The FCM sensitivity in our lab was 1/10~ 4 .②In 144 samples from 61 patients, NB cells were found in 23 of them morphologically(BM smear). All of those 23 samples were CD45~-/ CD81~+/ CD56~+ positive by FCM. Thirty-nine BM samples were cytologically negative by BM smear but CD45~-/ CD81~+/ CD56~+ positive by FCM. There was statistically significant difference between the two methods (P﹤0.01). ③ BM samples from 31 patients were positive for neuroblastoma by FCM at diagnosis, eleven of them became negative after average 4 courses of chemotherapy. All of those 11 patients remained alive without evidence of disease (median23mos,range8-38 months). In contrast, twenty patients whose BM samples were still positive, when they received the same chemotherapy, eleven of them were relapsed and 1 patient was died of disease(median17.5 months,range6-48 months). There was statistically significant difference in disease-free survival between the two groups(P﹤0.01).④MRD in BM was tested by FCM before PBSC harvest for 19 advanced neuroblastoma patients. Fourtheen was negative, two of them were relapsed. Eleven patients remained alive without evidence of disease (median 9 months after transplant,range 4-30 months). In contrast, other 5 patients whose BM remained positive before PBSC harvest, all of them were relapsed(median 10.5months after transplant,range 1-21 months). There was a statistically significant difference in disease-free survival after transplant between the two groups(P﹤0.05).Conclusions The method for detecting micrometastasis of NB in BM or peripheral blood using FCM was high sensitive and specific. It could evaluate the response of treatment by monitoring the MRD of BM. Positive NB MRD in BM during therapy was an unfavourable factor of prognosis.